Literature DB >> 15139984

HIV and hepatitis C coinfection within the CAESAR study.

J Amin1, M Kaye, S Skidmore, D Pillay, D A Cooper, G J Dore.   

Abstract

The declining incidence of AIDS-related opportunistic diseases among people with HIV infection has shifted the focus of clinical management to prevention and treatment of comorbidities such as chronic liver disease. The increased risk of hepatitis C virus (HCV)-related advanced liver disease in people with HIV infection makes early HCV diagnosis a priority. To assess HCV prevalence and predictors of HIV/HCV coinfection, we have conducted a retrospective analysis of people enrolled in the CAESAR (Canada, Australia, Europe, South Africa) study, a multinational randomized placebo-controlled study of the addition of lamivudine to background antiretroviral therapy. The impact of HCV on HIV disease progression was also examined. Anti-HCV antibody testing on 1649 CAESAR study participants demonstrated a HIV/HCV coinfection prevalence of 16.1%, which varied from 1.9% in South Africa to 48.6% in Italy. The strongest predictor of HIV/HCV coinfection was HIV exposure category (P<0.0001), with odds ratios (ORs) compared to homosexual as follows: injecting drug use (IDU), 365 [95% confidence interval (CI): 179-742]; transfusion or blood products, 32.2 (95% CI: 15.2-67.6); homosexual and IDU, 22.9 (95% CI: 8.5-62.1). The prevalence of HIV/HCV was low (3.7%) among homosexual men without reported IDU. Other predictors of HIV/HCV coinfection were alanine aminotransferase (ALT), country of residence, ethnicity and stage of HIV disease. A history of IDU or ALT > or =40 U/L at baseline had a positive predictive value (PPV) of 35%, negative predictive value (NPV) of 96%, sensitivity of 82% and specificity of 71% for HIV/HCV coinfection. HIV disease progression was similar in HIV monoinfected and HIV/HCV coinfected patients. People with HIV and a history of IDU or elevated liver function tests should be targeted for HCV testing. The low prevalence of HIV/HCV coinfection among homosexual men without a history of IDU suggests low efficiency of sexual HCV transmission.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139984     DOI: 10.1111/j.1468-1293.2004.00207.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  41 in total

1.  Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV.

Authors:  C L Cherry; J S Affandi; B J Brew; J Creighton; S Djauzi; D J Hooker; D Imran; A Kamarulzaman; P Kamerman; J C McArthur; R D Moore; P Price; K Smyth; I L Tan; S Vanar; A Wadley; S L Wesselingh; E Yunihastuti
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

3.  Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection.

Authors:  Michael C Clatts; Vivian Colón-López; Le M Giang; Lloyd A Goldsamt
Journal:  J Urban Health       Date:  2010-03       Impact factor: 3.671

4.  Liver Function Tests Abnormalities and Hepatitis B Virus & Hepatitis C Virus Co-infection in Human Immunodeficiency Virus (HIV)-infected Patients in India.

Authors:  P Puri; P K Sharma; A Lolusare; V K Sashindran; S Shrivastava; A K Nagpal
Journal:  J Clin Exp Hepatol       Date:  2016-12-29

5.  Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study.

Authors:  Clara Y Jones; Camille A Jones; Ira B Wilson; Tamsin A Knox; Andrew S Levey; Donna Spiegelman; Sherwood L Gorbach; Frederick Van Lente; Lesley A Stevens
Journal:  Am J Kidney Dis       Date:  2008-05-02       Impact factor: 8.860

Review 6.  Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person.

Authors:  O El-Sherif; D Back
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

7.  Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates.

Authors:  Fernando H Wolff; Sandra C Fuchs; Nêmora N T Barcellos; Paulo Ricardo de Alencastro; Maria Letícia R Ikeda; Ajácio B M Brandão; Maicon Falavigna; Flávio D Fuchs
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

Review 8.  Acute hepatitis C in an HIV-infected patient: a case report and review of literature.

Authors:  Todd H Driver; Norah Terrault; Varun Saxena
Journal:  J Gen Intern Med       Date:  2012-11-14       Impact factor: 5.128

9.  Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.

Authors:  Ting-Yi Chen; Eric L Ding; George R Seage Iii; Arthur Y Kim
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

10.  Problem drug use the public health imperative: what some of the literature says.

Authors:  Gez Bevan
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.